Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
Loading...
Embargo End Date
ICR Authors
Authors
de Jager, VD
Timens, W
Bayle, A
Botling, J
Brcic, L
Büttner, R
Fernandes, MGO
Havel, L
Hochmair, M
Hofman, P
Janssens, A
van Kempen, L
Kern, I
Machado, JC
Mohorčič, K
Popat, S
Ryška, A
Wolf, J
Schuuring, E
van der Wekken, AJ
Timens, W
Bayle, A
Botling, J
Brcic, L
Büttner, R
Fernandes, MGO
Havel, L
Hochmair, M
Hofman, P
Janssens, A
van Kempen, L
Kern, I
Machado, JC
Mohorčič, K
Popat, S
Ryška, A
Wolf, J
Schuuring, E
van der Wekken, AJ
Document Type
Journal Article
Date
2024-03-01
Date Accepted
2024-01-08
Abstract
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.
Citation
The Lancet Regional Health - Europe, 2024, 38 pp. 100839 -
Source Title
The Lancet Regional Health - Europe
Publisher
Elsevier BV
ISSN
2666-7762
eISSN
2666-7762
2666-7762
2666-7762